The AndroGel & 'Low T' Marketing Era
AndroGel, Direct-to-Consumer 'Low T' Campaigns, and the FDA's 2015 Class Labeling Response, Recent History
Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.
~5,246 participants (TRAVERSE). The written rationale for this grade is still being prepared.
- FDA
- Testosterone gels FDA-approved for classical hypogonadism; FDA restricted labeling and added warnings in 2015
Reference only. Not medical advice.
What can go wrong
Testosterone therapy is appropriate only for diagnosed hypogonadism and requires monitoring (hematocrit, PSA, lipids, symptoms). The FDA's 2015 action warned of a possible cardiovascular risk and against use for low testosterone from aging alone; treating non-specific aging symptoms without a rigorous diagnosis carries unnecessary risk.
This is something to take to a clinician. The Atlas can tell you what is known about the androgel & 'low t' marketing era in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
The recent history of testosterone as a consumer product. After AndroGel (a transdermal testosterone gel) launched around 2000, US testosterone prescribing surged through the late 2000s and early 2010s, propelled by direct-to-consumer 'Low T' advertising that reframed normal aging symptoms (fatigue, low libido, reduced drive) as a treatable hormone deficiency. Prescriptions and 'low T clinics' multiplied. In 2014-2015, after studies raised cardiovascular-safety questions, the FDA acted: it restricted approved testosterone indications to established hypogonadism, required a class-wide label change, and added a warning about possible cardiovascular risk and about misuse for aging. This is a case study in disease-mongering and regulatory correction.
How a hormone for diagnosed hypogonadism became a mass-market lifestyle product, then drew an FDA reckoning.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
Transdermal testosterone gels deliver testosterone across the skin to raise serum levels into the normal range; for a man with genuine hypogonadism this is legitimate replacement. The 'Low T' problem was not the drug's pharmacology but its marketing: campaigns broadened the perceived indication to ordinary, non-specific symptoms of aging, encouraging testing and treatment in men without a clear deficiency. The mechanism of the phenomenon, in other words, was commercial, converting a diagnosis-gated replacement therapy into a lifestyle product.
What people get wrong
Often said'Low T' is a clearly defined disease
ActuallyThe marketing term blurred genuine clinical hypogonadism with ordinary age-related symptom changes. The FDA's 2015 action specifically pushed back on treating low testosterone from aging alone as an approved indication.
Often saidThe 2015 FDA warning proved testosterone causes heart attacks
ActuallyThe cardiovascular signal was mixed and contested; the FDA required a cautionary label, not a finding of proven harm. The later TRAVERSE trial did not confirm a large cardiovascular excess in appropriately selected hypogonadal men.
Who profits, and who pushes back
US FDA (2015)
Approved testosterone use is for hypogonadism from defined medical conditions, not for low testosterone due to aging; products carry a possible cardiovascular-risk warning.
How we got here
When AbbVie/Abbott's AndroGel and competing gels (Testim, later Axiron, Fortesta, and others) made testosterone easy to apply, the market expanded far beyond the relatively small population with diagnosed organic hypogonadism. Through the late 2000s and into the early 2010s, direct-to-consumer advertising popularized the term 'Low T,' encouraging middle-aged men to attribute fatigue, low libido, weight gain, and flagging motivation to testosterone deficiency and to ask for testing and treatment. US testosterone prescriptions rose several-fold, and dedicated 'low T clinics' proliferated; a substantial share of men starting testosterone reportedly had no rigorous biochemical diagnosis of hypogonadism. The correction came on safety grounds. Around 2013-2014, several observational studies and a trial raised the possibility of increased cardiovascular events with testosterone therapy (the data were mixed and contested), and the FDA convened an advisory committee. In 2015 the FDA clarified that testosterone products are approved only for men with hypogonadism due to defined medical conditions, not for low testosterone from aging alone, required a class-wide labeling change to that effect, and added a warning about a possible increased risk of heart attack and stroke. (Later evidence, including the large TRAVERSE trial reported in 2023, did not confirm a major excess of cardiovascular events in appropriately selected hypogonadal men, nuancing but not erasing the earlier caution.) The AndroGel/'Low T' era is recent history that directly prefigures today's telehealth testosterone marketplace: the same dynamic of broadening a legitimate replacement therapy into an aging-and-vitality consumer product, now playing out online.
- ~2000AndroGel launches; convenient transdermal testosterone arrives
- Late 2000s-early 2010s'Low T' DTC advertising; prescriptions surge; low-T clinics spread
- 2013-2014Studies raise possible cardiovascular-risk signal; FDA reviews
- 2015FDA restricts indication to hypogonadism, mandates class label change and CV warning
- 2023TRAVERSE trial reported; no large CV excess in appropriately selected hypogonadal men
What we do not know
- How much of the mid-2010s prescribing decline was the FDA action versus the cardiovascular-risk publicity?
- Does the telehealth model reproduce the 'Low T' diagnosis gap, and how will TRAVERSE-era evidence reshape marketing?
At a glance
- Flagship product
- AndroGel (transdermal testosterone gel), launched ~2000
- Marketing hook
- 'Low T' direct-to-consumer campaigns (~late 2000s-early 2010s)
- Prescribing surge
- Large multi-fold rise in US testosterone prescriptions through ~2013
- Safety trigger
- 2013-2014 studies raising possible cardiovascular concerns
- FDA action
- 2015: indication restricted to hypogonadism; class label change; CV warning
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about The AndroGel & 'Low T' Marketing Era. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
FDA Drug Safety Communication on testosterone products2015Indication limited to hypogonadism from defined conditions; class label change and possible-CV-risk warning
TRAVERSE cardiovascular safety trial2023No major excess of cardiovascular events vs placebo in appropriately selected hypogonadal men (~5,000+ participants)